Amgen (NASDAQ:AMGN) Shares Acquired Rep. Maria Elvira Salazar

Representative Maria Elvira Salazar (Republican-Florida) recently bought shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on April 21st, the Representative disclosed that they had bought between $15,001 and $50,000 in Amgen stock on March 24th. The trade occurred in the Representative’s “UBS IRA ACCOUNT” account.

Representative Maria Elvira Salazar also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of FedEx (NYSE:FDX) on 3/25/2026.
• Purchased $1,001 – $15,000 in shares of United Rentals (NYSE:URI) on 3/25/2026.
• Purchased $1,001 – $15,000 in shares of GE Aerospace (NYSE:GE) on 3/24/2026.
• Purchased $15,001 – $50,000 in shares of Honeywell International (NASDAQ:HON) on 3/24/2026.
• Purchased $15,001 – $50,000 in shares of The Goldman Sachs Group (NYSE:GS) on 3/19/2026.
• Purchased $15,001 – $50,000 in shares of Ulta Beauty (NASDAQ:ULTA) on 3/19/2026.
• Purchased $1,001 – $15,000 in shares of Citigroup (NYSE:C) on 3/19/2026.
• Purchased $15,001 – $50,000 in shares of Corning (NYSE:GLW) on 3/19/2026.
• Purchased $1,001 – $15,000 in shares of Peloton Interactive (NASDAQ:PTON) on 3/19/2026.
• Purchased $15,001 – $50,000 in shares of RH (NYSE:RH) on 3/19/2026.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $348.62 on Friday. The company’s 50-day moving average is $361.24 and its 200 day moving average is $338.80. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The company has a market capitalization of $188.14 billion, a P/E ratio of 24.50, a price-to-earnings-growth ratio of 3.62 and a beta of 0.47. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm’s quarterly revenue was up 8.6% on a year-over-year basis. During the same period in the previous year, the firm earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities research analysts forecast that Amgen Inc. will post 22.18 earnings per share for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s payout ratio is 70.84%.

Institutional Investors Weigh In On Amgen

A number of institutional investors and hedge funds have recently modified their holdings of AMGN. Dogwood Wealth Management LLC increased its position in shares of Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after purchasing an additional 55 shares during the last quarter. Anfield Capital Management LLC grew its position in Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 70 shares during the last quarter. Board of the Pension Protection Fund bought a new position in Amgen during the fourth quarter valued at approximately $26,000. Tower View Wealth Management LLC grew its position in Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 63 shares during the last quarter. Finally, Manning & Napier Advisors LLC grew its position in Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 32 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Completed early-stage cancer study — Amgen announced completion of a Phase 1/2 MTAP?null cancer combination study, a pipeline de?risking milestone that could support long?term value if follow?up data are positive. Amgen Marks Key Milestone With Completion of Early MTAP-Null Cancer Combo Study
• Positive Sentiment: Analyst price?target lift — Guggenheim nudged its price target to $351 (from $347) ahead of earnings, a modest endorsement that may support the stock despite the firm keeping a Neutral rating. Guggenheim Adjusts Amgen Inc. (AMGN) PT to $351, Cites Updated Model Ahead of Earnings
• Neutral Sentiment: CTO retirement and leadership realignment — Amgen announced David M. Reese, M.D. will retire as EVP & Chief Technology Officer effective June 30, with a strategic leadership realignment emphasizing integration of biology and technology; operationally notable but framed as orderly. AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
• Neutral Sentiment: New/maintained Hold coverage — Bernstein and Canaccord Genuity are on Hold for AMGN (Canaccord initiated coverage with a Hold), indicating limited near?term analyst conviction. Amgen (AMGN) Receives a Hold from Bernstein Canaccord Genuity initiates coverage of Amgen (AMGN) with hold recommendation
• Negative Sentiment: Q1 earnings expected to decline — previews from Zacks/Yahoo suggest Amgen lacks the setup for an earnings beat in the upcoming Q1 report, creating downside risk around the release. Earnings Preview: Amgen (AMGN) Q1 Earnings Expected to Decline
• Negative Sentiment: Insider selling — filings show roughly US$4.1M of insider share sales over the past year, which some investors interpret as a cautionary signal. Amgen Insiders Sell US$4.1m Of Stock, Possibly Signalling Caution

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Freedom Capital downgraded shares of Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 12th. Piper Sandler boosted their price target on shares of Amgen from $381.00 to $432.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Morgan Stanley boosted their price target on shares of Amgen from $309.00 to $326.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. Canaccord Genuity Group began coverage on shares of Amgen in a report on Monday. They set a “hold” rating and a $366.00 price objective on the stock. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $350.00 price objective on shares of Amgen in a report on Wednesday, April 8th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Amgen presently has an average rating of “Hold” and an average target price of $356.62.

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida’s 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida’s 27th Congressional District. She won in the general election on November 5, 2024.

Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.